Education/Working Experience
Postdoctoral Research Fellow, 1994-1999
Division of Nephrology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN37232
Assistant Professor of Medicine 1999,09-2002,09
Division of Nephrology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN37232
Participation in the Academic Community
Member of American Society of Nephrology (ASN);
Member of International Society of Nephrology (ISN);
Member of American Physiological Society (APS)
Member of Chinese Society of Physiology (CSP)
Member of American Diabetes Association (ADA)
Member of American Association for the Advancement of Science (AAAS)
Publication
Selected 10 publications (140 articles in total):
1. Guan Y, Zhang Y, Breyer R, Fowler, B, Davis L, Hebert, RL, Breyer MD: PGE2 inhibits renal collecting duct Na+ absorption by activating the EP1 receptor.J. Clin. Invest. 1998;102:194-201
2. Guan Y and Breyer MD. Peroxisome proliferator-activated receptors (PPARs): Novel therapeutic targets in renal disease. Kidney Int. 2001; 60 (1):14-30.
3. Guan Y. Invited Review: PPAR family and renal complications of the metabolic syndrome. J. Am. Soc. Nephrol. 2004 Nov;15(11):2801-15
4. Guan Y, Hao C, Rao R, Cha DR, Kohan D, Magnuson M, Zhang Y, Breyer MD: PPARg regulates systemic fluid volume by activating sodium absorption in the collecting duct.Nature Medicine 2005 Aug;11(8):861-866;
5. Park CW, Zhang Y, Zhang X, Wu J, Chen L, Cha DR, Su D, Hwang MT, Fan X, Davis L, Striker G, Zheng F, Breyer M, Guan Y*.PPARalpha agonist fenofibrate improves diabetic nephropathy in db/db mice.Kidney Int. 2006 May;69(9):1511-7.
6. Guan Y*, Zhang Y, Wu J, Qi Z, Yang G, Dou D, Gao Y, Chen L, Zhang X, Davis LS, Wei M, Fan X, Carmosino M, Hao C, Imig JD, Breyer RM, Breyer MD. Antihypertensive effects of selective prostaglandin E2 receptor subtype 1targeting.J Clin Invest.2007;117(9):2496-505.
7. Yang H, Zhang X， Kong X， Zhao P, Li J, Han Q, YangJ, Zhu Y, Guan Y*. AMP-activated protein kinase potentiates hypertonicity-induced apoptosis by blocking the NFκB/COX-2 survival pathway in renal medullary interstitial cells.J Am SocNephrol2011 Oct;22(10):1897-911;
8. Wu J, Li S, Wang W, Li J, Chi Y, Kong X, Zhou Y, Yang J, Gustafsson JÅ, Guan Y*. Thyroid hormone-responsive spot 14 protein promotes hepatic lipogenesis, and its expression is regulated by LXRα through an SREBP1c-dependent mechanism.Hepatology2013 Aug;58(2):617-28.;
9. Su W, Wang Y, Jia X, Wu W, Li L, Tian X, Li S, Wang C, Xu H, Cao J, Han Q, Xu S, Chen Y, Zhong Y, Zhang X, Liu P, Gustafsson JÅ, Guan Y*. Comparative proteomic study reveals 17β-HSD13 as a pathogenic protein in nonalcoholic fatty liver disease.ProcNatlAcadSci U S A. 2014 Aug 5;111(31):11437-42;
Gao M, Cao R, Du S, Jia X, Zheng S, Huang S, Han Q, Liu J, Zhang X, Miao Y, Kang J, Gustafsson JÅ, Guan Y. Disruption of prostaglandin E2 receptor EP4 impairs urinary concentration via decreasing aquaporin 2 in renal collecting ducts.ProcNatlAcadSci U S A. 2015 Jul 7;112(27):8397-402.
Research Projects/Grants
Active:
MajorProject of National Natural Science Foundation, sub project “Mechanisms of Transcriptional and posttranscriptional regulation of genes involved in glucose metabolism”, #81390351, 2014-2018
The Ministry of Science and Technology of China: the “973” National Basic Research Program of China on NAFLD and Hyperlipidemia ( 2012CB517500),Chief Scientist;
National Natural Science Foundation, the Outstanding Young Investigator Award, 2007;
The National Nature Science Foundation of China (NNSFC): #30870905, #81030003;The Ministry of Science and Technology of China: the “973” National Basic Research Program of China ( 2010CB8912500&2012CB517500);
Research grant from AstraZeneca, #SEML-89HGV2, #SEML-89HGR7;
Research grant from AstraZeneca China;
Research grant from Eli Lilly Company
Completed:
NIDDK-PO1-038226
NIH RO1 DK065074
The Ministry of Education of China: #104001
The National Nature Science Foundation of China (NNSFC): #30340084,
#30530340, #30271521, #30670766
American Heart Association – Southeast Affiliate (AHA #016200B)
Atorvastatin Research Awards (Pfizer Pharmaceutics)
GenZyme Renal Innovation Program (GRIP)
The Ministry of Science and Technology of China: the “973” National Basic Research Program of China (Diabetes, 2006CB503900)
The “985” project: #985-2-037-39, #985-2-001-111 & #985-2-003-112
